Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis.

ABSTRACT:

Objective

To examine the safety, effectiveness, and cost effectiveness of long acting insulin for type 1 diabetes.

Design

Systematic review and network meta-analysis.

Data sources

Medline, Cochrane Central Register of Controlled Trials, Embase, and grey literature were searched through January 2013.

Study selection

Randomized controlled trials or non-randomized studies of long acting (glargine, detemir) and intermediate acting (neutral protamine Hagedorn (NPH), lente) insulin for adults with type 1 diabetes were included.

Results

39 studies (27 randomized controlled trials including 7496 patients) were included after screening of 6501 titles/abstracts and 190 full text articles. Glargine once daily, detemir once daily, and detemir once/twice daily signif

SUBMITTER: Tricco AC 

PROVIDER: S-EPMC4199252 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature